Illinois Municipal Retirement Fund Has $3.70 Million Stock Holdings in Glaukos Corporation $GKOS

Illinois Municipal Retirement Fund lifted its holdings in Glaukos Corporation (NYSE:GKOS) by 13.3% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 34,395 shares of the medical instruments supplier’s stock after buying an additional 4,025 shares during the quarter. Illinois Municipal Retirement Fund owned about 0.06% of Glaukos worth $3,703,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Janus Henderson Group PLC increased its position in Glaukos by 183.4% in the 4th quarter. Janus Henderson Group PLC now owns 3,018,787 shares of the medical instruments supplier’s stock valued at $340,855,000 after acquiring an additional 1,953,578 shares in the last quarter. Primecap Management Co. CA lifted its position in shares of Glaukos by 49.8% during the fourth quarter. Primecap Management Co. CA now owns 3,376,928 shares of the medical instruments supplier’s stock worth $381,289,000 after purchasing an additional 1,123,140 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Glaukos by 209.0% during the fourth quarter. Goldman Sachs Group Inc. now owns 1,350,425 shares of the medical instruments supplier’s stock worth $152,476,000 after purchasing an additional 913,458 shares in the last quarter. Millennium Management LLC grew its stake in shares of Glaukos by 75.3% during the fourth quarter. Millennium Management LLC now owns 1,609,699 shares of the medical instruments supplier’s stock valued at $181,751,000 after purchasing an additional 691,289 shares during the last quarter. Finally, UBS Group AG grew its stake in shares of Glaukos by 316.0% during the fourth quarter. UBS Group AG now owns 873,942 shares of the medical instruments supplier’s stock valued at $98,677,000 after purchasing an additional 663,849 shares during the last quarter. Institutional investors and hedge funds own 99.04% of the company’s stock.

Glaukos Trading Up 1.0%

Shares of NYSE GKOS opened at $156.97 on Friday. The company’s 50 day simple moving average is $134.39 and its 200 day simple moving average is $122.04. Glaukos Corporation has a fifty-two week low of $73.16 and a fifty-two week high of $161.53. The firm has a market capitalization of $9.22 billion, a P/E ratio of -47.86 and a beta of 0.75. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.43 and a quick ratio of 4.73.

Glaukos (NYSE:GKOS) last released its earnings results on Wednesday, April 29th. The medical instruments supplier reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.12. The firm had revenue of $150.57 million during the quarter, compared to analyst estimates of $137.00 million. Glaukos had a negative net margin of 34.34% and a negative return on equity of 6.92%. The business’s quarterly revenue was up 41.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.22) EPS. On average, analysts predict that Glaukos Corporation will post -0.57 EPS for the current year.

Analysts Set New Price Targets

Several research analysts recently weighed in on GKOS shares. Wall Street Zen cut shares of Glaukos from a “buy” rating to a “hold” rating in a research report on Saturday. JPMorgan Chase & Co. increased their price objective on Glaukos from $120.00 to $140.00 and gave the company an “overweight” rating in a research report on Thursday, April 30th. Piper Sandler restated an “overweight” rating and set a $165.00 target price on shares of Glaukos in a research report on Wednesday, July 1st. HC Wainwright assumed coverage on Glaukos in a research note on Monday, July 6th. They set a “buy” rating and a $168.00 price target on the stock. Finally, Truist Financial upped their price target on Glaukos from $160.00 to $180.00 and gave the company a “buy” rating in a research note on Thursday. Thirteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $154.85.

Insider Buying and Selling

In related news, CFO Alex R. Thurman sold 10,000 shares of the company’s stock in a transaction dated Thursday, April 30th. The stock was sold at an average price of $140.00, for a total value of $1,400,000.00. Following the completion of the sale, the chief financial officer owned 43,681 shares in the company, valued at approximately $6,115,340. This represents a 18.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Joseph E. Gilliam sold 19,573 shares of the stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $143.54, for a total value of $2,809,508.42. Following the completion of the transaction, the chief operating officer directly owned 73,419 shares in the company, valued at $10,538,563.26. The trade was a 21.05% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 61,273 shares of company stock valued at $8,882,003 over the last 90 days. Company insiders own 5.90% of the company’s stock.

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.